A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
暂无分享，去创建一个
D. DeLair | M. Shahin | P. Thaker | Austin Miller | C. Aghajanian | H. Lankes | R. Soslow | J. Moroney | D. Zamarin | R. Debernardo | S. Segura | R. O’Cearbhaill | K. Moore | Andrea Wahner-Hendrickson | S. Chavan